Lupin launches generic Kapvay tablets in the US
13 February 2018 | News
It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications
Pharma major Lupin announced the launch of its Clonidine Hydrochloride extended-release tablets, 0.1mg, having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Clonidine Hydrochloride ER tablets is the generic equivalent of Concordia International Corp’s Kapvay® tablets.
It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.
Kapvay® tablets had annual sales of approximately USD 66 million in the US (IQVIA MAT December 2017).
